Targeting G1–S-checkpoint-compromised cancers with cyclin A/B RxL inhibitors
Targeting G1–S-checkpoint-compromised cancers with cyclin A/B RxL inhibitors Summary This Nature paper reports the design and preclinical characterisation of orally bioavailable macrocyclic peptides that block RxL-mediated substrate docking on cyclins…
